Logo Logo
Group by: Item Type | Date
Number of items: 2.

Journal article

Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M.-A.; Im, S.-A.; Ahn, J.-H.; Gion, M.; Baron-Hay, S.; Boileau, J.-F.; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V. und O'Shaughnessy, J. (2022): Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. In: New England Journal of Medicine, Vol. 386, No. 6: pp. 556-567

Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A. und Harbeck, N. (2016): Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer. In: Annals of Oncology, Vol. 27

This list was generated on Sun Dec 8 05:16:36 2024 CET.